Singh Shruti, Nimavat Nirav, Kumar Singh Amarjeet, Ahmad Shamshad, Sinha Nishi
Department of Pharmacology, AIIMS, Patna, Bihar, India.
Department of Community Medicine, SBKS MIRC, Sumandeep Vidyapeeth Deemed to be University, Vadodara, Gujarat, India.
Int J Gen Med. 2021 Jun 15;14:2523-2531. doi: 10.2147/IJGM.S309003. eCollection 2021.
The world is facing the most challenging pandemic in the 21st century. The developed and developing countries are facing the burden equally and no proven treatment options available. Recent studies suggest the plausibility of vitamin D therapy and prophylaxis for COVID-19, in the setting where the deficiency is more prevalent. Though evaluation of vitamin D status is not a routine in India, the present study focuses on the level of Vitamin d among COVID-19 patients.
The study was a hospital-based cross-sectional to find the status of vitamin D among COVID-19 patients in a tertiary care hospital, Patna, Bihar, India. The demographic, comorbidity data were taken, and the level of vitamin D was measured by a chemiluminescence-based immunoassay analyzer. The analysis compared the level of deficiency and insufficiency among different groups of COVID-19 patients. The role of DM and HTN as risk factors for mortality was compared.
Among the total study participants (156), 42.31% were obese and 17.31% were severe as per clinical severity. The total prevalence of vitamin D deficiency was 58.97% and insufficiency was 89.1%. The prevalence was found high among male (61.02%), overweight (65.52%), and severe (62.96%) patients. The severity increases with advanced age (p<0.05) and important risk factors for mortality are DM, HTN, and advanced age.
The level of vitamin D can be assessed for the prognosis of COIVD-19 patients and help to modify the treatment protocol. Appropriate therapeutic/preventive intervention of vitamin D can alter the course and severity of COVID-19.
世界正面临21世纪最具挑战性的大流行。发达国家和发展中国家同样面临负担,且尚无经证实的治疗方案。最近的研究表明,在维生素D缺乏更为普遍的情况下,维生素D疗法和预防措施对2019冠状病毒病(COVID-19)具有合理性。尽管在印度,评估维生素D状况并非常规操作,但本研究关注COVID-19患者的维生素D水平。
本研究是一项基于医院的横断面研究,旨在了解印度比哈尔邦巴特那一家三级护理医院中COVID-19患者的维生素D状况。收集了人口统计学和合并症数据,并通过基于化学发光的免疫分析分析仪测量维生素D水平。该分析比较了不同组COVID-19患者的缺乏和不足水平。比较了糖尿病和高血压作为死亡风险因素的作用。
在全部研究参与者(156人)中,根据临床严重程度,42.31%为肥胖,17.31%为重症。维生素D缺乏的总患病率为58.97%,不足率为89.1%。在男性(61.02%)、超重(65.52%)和重症(62.96%)患者中,患病率较高。严重程度随年龄增长而增加(p<0.05),死亡的重要风险因素是糖尿病、高血压和高龄。
可以评估维生素D水平以判断COVID-19患者的预后,并有助于修改治疗方案。对维生素D进行适当的治疗/预防干预可以改变COVID-19的病程和严重程度。